Editor's Note Healthcare costs are expected to rise between 7% and 8% in 2025, according to a report from PwC's Health Research Institute. As detailed in a July 17 article from Fierce Healthcare, PwC projections for an 8% increase in the group market and 7.5% in the individual market would…

Read More

Editor's Note Roux-en-Y gastric bypass surgery kept type 2 diabetes in remission for up to 15 years and maintained most of the weight loss for up to 20 years in a long-term study, according to a June 12 report in SciTech Daily. Presented the same day at The American Society…

Read More

Editor's Note Bariatric surgery provides longer-lasting, more effective weight loss than GLP-1 receptor agonists and lifestyle interventions, according to systematic reviews of medical literature from 2020 to 2024. Medical Xpress reported the news June 11. Presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2024 Annual Scientific Meeting,…

Read More

Editor's Note Preoperative use of GLP-1 receptor agonists (RA) medications such as Ozempic and Wegovy is safe, according to a study published in the June issue of the American Journal of Gastroenterology. Controversy has swirled around these drugs due to the risk of slowed stomach emptying increasing a patient’s odds…

Read More

Editor's Note Semaglutide, the active ingredient in Ozempic diabetes treatment and Wegovy weight-loss treatment, outperformed a placebo and demonstrated capacity to reduce risk of death from kidney-related or cardiovascular causes in a recent study of patients with type 2 diabetes and chronic kidney disease spearheaded by manufacturer Novo Nordisk. Published…

Read More

Editor's Note Popular weight-loss \ drug semaglutide could significantly increase risk for repeat operations patients with diabetes who undergo lumbar surgery. According to a May 8 report in Medscape Medical News, the findings are pending review for publication and reportedly provides the first evidence on the impact of semaglutide on…

Read More

Editor's Note Recent research suggests that minimizing the risk of perioperative pulmonary aspiration in diabetic patients does not require different fasting instructions. However, at least one expert has questioned the results, and widespread glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of both type 2 diabetes and weight loss can…

Read More

Editor's Note A recent analysis of insurance claims data suggests weight-loss medications like Ozempic (semaglutide), Trulicity (dulaglutide), and other glucagon-like peptide-1 (GLP-1) receptor agonists do not increase risks associated with undergoing anesthesia. As reported April 22 in MedPage Today, these finding that contradicts a June 2023 recommendation from the American Society of…

Read More

Editor's Note Gastrointestinal endoscopy could increase the risk of aspirational pneumonia in patients using GLP-1 receptor agonists (RAs) to manage weight or treat diabetes, according to an April 1 report from MedPage today. Citing research published in the journal Gastroenterology by a team led by Kevin Sheng-Kai Ma, DDS, of…

Read More

Editor's Note Popular weight-loss drugs like Ozempic and Mounjaro could lead to complications in surgical procedures, according to study published March 6 in the journal JAMA Surgery.  The study focused on drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) which are used to treat diabetes and obesity. The drugs, which…

Read More